Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly …
Biotechnology
US, South San Francisco [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Day One Biopharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2023 | -2.0200 | -2.276 | 0 | 0 | -132 | -179 | -141 | 0 | -147 | 0 | 61 | 0 |
| 2024 | -2.3700 | -0.744 | 0 | 113 | -188 | -84 | -206 | 0 | -206 | 0 | 75 | 0 |
| 2025 | - | -1.165 | - | 162 | - | -116 | - | 0 | - | 0 | - | 0 |
| 2026 | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F3X/td> | - | 2.F31/td> | - | 2.F31 | - | 2.F31 |
| 2027 | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F4X/td> | - | 1.F41/td> | - | 1.F41 | - | 1.F41 |
| 2028 | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F51/td> | - | 0.F51 | - | 0.F51 |